Clinicopathological features analysis of BRAF V600 mutation non-small cell lung cancer
10.13315/j.cnki.cjcep.2025.06.010
- VernacularTitle:BRAF V600突变非小细胞肺癌临床病理特征分析
- Author:
Yu GUO
1
;
Xiaomin WANG
1
Author Information
1. 陕西省肿瘤医院病理科,西安 710061
- Publication Type:Journal Article
- Keywords:
non-small cell lung cancer;
BRAF;
real-time quantitative PCR;
clinicopathological features
- From:
Chinese Journal of Clinical and Experimental Pathology
2025;41(6):759-764
- CountryChina
- Language:Chinese
-
Abstract:
Purpose To investigate the clinicopathological features of BRAF V600-mutant non-small cell lung cancer(NSCLC).Methods A total of 2 069 NSCLC specimens were collected.Real-time quantitative PCR was used to detect mutations in the BRAF,EGFR,KRAS,HER2,and MET genes,as well as fusion status of ALK,ROS1,and RET.PD-L1 protein expression was evaluated by immunohistochemistry.The correlation between BRAF V600 mu-tation and patients' age,sex,smoking history,tumor size,tumor stage,lymph node metastasis,TNM stage,PD-L1 expression,histological subtype,and degree of differentiation was analyzed.Results Among the 2 069 NSCLC cases,43(2.08％)harbored BRAF V600 mutations,including 27 females and 16 males,with a median age of 64 years(range,47-81 years).Histologically,41 cases were adenocarcinomas and 2 cases were large-cell carcinomas.15 pa-tients underwent surgical resection,of whom 4(26.7％)exhibited micropapillary components.Clinical TNM stage dis-tribution was:Ⅰ+Ⅱ in 13 cases and Ⅲ+Ⅳ in 30 cases.Three cases had concurrent mutations in both BRAF V600 and EGFR.Among BRAF-mutant tumors tested for PD-L1,63.6％(7/11)were PD-L1-positive(≥1％).BRAF V600 mutation NSCLC patients were associated with patient sex,smoking history and histologic subtypes.17 patients received chemotherapy,and 7 patients received BRAF-targeted therapy.Survival analysis indicated that the median progression-free survival(PFS)was longer in the BRAF-targeted therapy group than in the chemotherapy group(13 vs 11 months),although the difference was not statistically significant(P=0.197).Conclusion Female patients and never-smokers,and those with solid or acinar adenocarcinoma subtypes exhibit higher rates of BRAF V600 mutation.
